Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH

Iterum Therapeutics plc

Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.
Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.
Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.
Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.